Jan 7 (Reuters) - Eli Lilly ‌will ​buy autoimmune drug developer ‌Ventyx Biosciences for $1.2 billion in cash, the companies ...

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 ...

Lithium Argentina will provide additional discussion and analysis regarding its full-year and Q4 2025 results when the Company reports its quarterly and full-year results in March 2026.

Cogentrix is a leading developer, owner, and operator of power generation assets across the country, with a more than four-decade track record of delivering dependable power to communities and ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Despite near-term revenue pressure from upcoming patent expirations, Pfizer’s expanding late-stage pipeline, led by oncology and supported by growing investments in obesity, vaccines, and rare ...

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation (“BTD”) to their blockbuster antibody-drug conjugate (ADC), Enhertu, ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant therapy. Enhertu's iDFS benefits were consistent across HER2 expression ...

Trastuzumab deruxtecan plus pertuzumab reduced the risk of disease progression or death by 44% compared with THP, with a median PFS of 40.7 months. The Food and Drug Administration (FDA) has approved ...

U.S. retail sales decelerated this fall, the Census Bureau said Tuesday. The October report, delayed by the recent government shutdown, showed that sales at retail stores were flat in October compared ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...